百匹目の猿現象

 

Research

In 1967, Geisinger was awarded a federal grant to study the effectiveness of medications to prevent heart attacks or their recurrence.^[24] In 1974, the Central Pennsylvania Chapter of the Arthritis Foundation awarded a grant to Geisinger to study the potential treatment of Raynaud syndrome with drugs normally used to treat high blood pressure at that time.^[25]

Geisinger has a database of electronic health records (EHR), and set up a genetics research program called MyCode in 2007.^[23] The use of EHR allows longitudinal study of patient outcomes through a study called "DiscovEHR".^[26][27][28] The program uses gene sequencing by the biotechnology company Regeneron Pharmaceuticals.^[29] The National Institutes of Health awarded a grant of US$5.5 million to the research program in 2016.^[29] The program was expanded to include whole exome sequencing in 2018.^[22] Using the patient volunteers' genetic data stored in its MyCode program, Geisinger has conducted or collaborated on genetic research studies aimed at identifying potential links between genetic variants and risk factors for certain diseases.^[23] Geisinger contributed data from 35,000 of its patients to a 2016 Johns Hopkins University study that demonstrated linkages between asthma and fracking.^[30] In 2021, a Regeneron-led study partially based on genetic data from the MyCode biobank identified a genetic variant that appears to lower obesity risk.^[31][32][33]

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.^[1] Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors. 

Experimental treatment for COVID-19

Main article: Casirivimab/imdevimab

On February 4, 2020, the U.S. Department of Health and Human Services, which already worked with Regeneron, announced that Regeneron would pursue monoclonal antibodies to fight COVID-19.^[9]

In July 2020, under Operation Warp Speed, Regeneron was awarded a $450 million government contract to manufacture and supply its experimental treatment REGN-COV2, an artificial "antibody cocktail" which was then undergoing clinical trials for its potential both to treat people with COVID-19 and to prevent SARS-CoV-2 coronavirus infection.^[10][11][12] The $450 million came from the Biomedical Advanced Research and Development Authority (BARDA), the DoD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, and Army Contracting Command. Regeneron expected to produce 70,000–300,000 treatment doses or 420,000–1,300,000 prevention doses. "By funding this manufacturing effort, the federal government will own the doses expected to result from the demonstration project," the government said in its July 7 news release.^[13] Regeneron similarly said in its own news release that same day that "the government has committed to making doses from these lots available to the American people at no cost and would be responsible for their distribution," noting that this depended on the government granting emergency use authorization or product approval.^[14] California based laboratory, FOMAT, is part of the clinical investigation through their doctors Augusto and Nicholas Focil.^[15]

In October 2020 when U.S. President Donald Trump was infected with COVID-19 and taken to Walter Reed National Military Medical Center in Bethesda, Maryland, he was administered REGN-COV2.^[16] His doctors obtained it from Regeneron via a compassionate use request (as clinical trials had not yet been completed and the drug had not yet been approved by the US Food and Drug Administration (FDA)).^[17] On October 7, Trump posted a five-minute video to Twitter reasserting that this drug should be "free."^[18] That same day, Regeneron filed with the FDA for emergency use authorization. In the filing, it specified that it currently had 50,000 doses and that it expected to reach a total of 300,000 doses "within the next few months."^[19] The FDA granted approval for emergency use authorization in November 2020.^[20]

2021年12月28日火曜日

南アから武漢株ではなくオミクロン株こそがオリジナル・ストレインかもしれないという非常に不都合な研究結果

https://tokumei10.blogspot.com/2021/12/blog-post_57.html

百匹目の猿現象（ひゃっぴきめのさるげんしょう、英: Hundredth Monkey Effect, Hundredth Monkey Phenomenon）とは、生物学の現象と称して生物学者のライアル・ワトソンが創作した架空の物語である。

宮崎県串間市の幸島に棲息するニホンザルの一頭がイモを洗って食べる事を覚え、同行動を取る猿の数が閾値（ワトソンは仮に100匹としている）を超えたときその行動が群れ全体に広がり、さらに場所を隔てた大分県高崎山の猿の群れでも突然この行動が見られるようになったという筋書きであり、このように「ある行動、考えなどが、ある一定数を超えると、これが接触のない同類の仲間にも伝播する」という超常現象の実例とされていた。

 

幸島のサル

幸島は古くからサル（ニホンザル）が棲息していたといわれ、大正時代にも旧東北帝国大学などが調査を行っており、90頭の棲息が確認されている。なぜ、人里離れた小島に野生猿が棲息していたかは不明であるが、人為的に持ち込まれたという説が有力視されている。その中で最も有名なのが、平家の落人が小島に隠棲した際に猿を神使として飼い始めたというものであるが、伝承の域を出ない。もっとも、後のサル研究の中では本土との行き来が少数例ながら観察されているので、自然分布の可能性もある。地元では幸島のサルを「和子様（わこさま）」と呼び、神の使いと見做して大切にしてきた。

しかし、太平洋戦争後、米軍の統治下にあった頃、米軍司令官にペットとして献上するために子ザルが狩られてしまい、サルの個体数は激減した。後述する京都大学の研究員らがこの島を訪れたとき、個体数はわずか9頭しか確認できなかった（実際はもっと生存していたとも考えられるが、前述の理由から人間を恐れて山中に逃げ込み、隠れて出てこなかったと推測される^[要出典]）。 

百匹目の猿 船井幸雄 集合的無意識 - 料理旅館大正楼

https://www.taishoro.com › saru

百匹目の猿。船井総研会長、船井幸雄氏の著作。奈良の旅館、大正楼の主人による読後コメントです。「百匹目の猿」に書かれていることは、シンクロニシティや集合的 ...

百匹目の猿現象 - 舩井幸雄.com｜舩井幸雄の今月のクローズ ...

https://www.funaiyukio.com › close-up › index_0801

船井先生が提唱しているように、たとえば志をもった5000人のあなたが手をつなぎ、「百匹目の猿現象」を起こしましょうということ。この世に生を受け、生かされている ...

百匹目の猿 思いが世界を変える 船井幸雄 書評と感想【読書の ...

https://plus-work.jp › circle › book › hyapikime

猿がイモを洗う、しかも全く違う地域で！ ... 思いが世界を変える. 著者：船井幸雄 ... ほどなくして、猿の群れ全体が「サツマイモ洗う」ということをしだします。

site://tokumei10.blogspot.com 船井幸雄

site://tokumei10.blogspot.com 船井幸雄

site://tokumei10.blogspot.com 船井幸雄

１００匹の猿がDeath汁を接種すると・・・（爆ｗｗｗｗｗｗｗｗｗｗｗｗ